MiNK Therapeutics, Inc. announced its first-quarter 2025 financial results and highlighted significant progress in its development of allogeneic invariant natural killer T (iNKT) cell therapies. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results